Nubeqa Receives New Indication for Prostate Cancer

August 5, 2022

The U.S. FDA has approved Nubeqa® (darolutamide – Bayer) for use in combination with docetaxel to treat metastatic hormone-sensitive prostate cancer in males.

Nubeqa first received FDA approval in 2019 and is also indicated to treat non-metastatic castration-resistant prostate cancer.
Recommended dosing is 600mg (two 300mg tablets) taken by mouth twice daily with food.

Related News

Benefit Advisors & Employees - Want to know more?

Members: Please call the number on the back of your ID card or e-mail member.services@benecardpbf.com Clients: Contact your Client Relations Manager

By submitting this form, you are consenting to receive marketing emails from: Benecard Services, LLC. (Lawrenceville, NJ 08648), https://www.benecard.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact.

Nubeqa Receives New Indication for Prostate Cancer

August 5, 2022

Related News

RISVAN®

VAFSEO®

WINREVAIR™

Benefit Advisors & Employees - Want to know more?

Benecard

Newsletter